54
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Effects of the COX-2 Inhibitor FK3311 on Ischemia—Reperfusion Injury in the Rat Lung

, MD, , MD, , MD, , MD & , MD
Pages 175-180 | Published online: 09 Jul 2009
 

Abstract

Ischemia–reperfusion injury is induced by activation of the arachidonic acid cascade following the induction of cyclooxygenase-2. This study evaluated the effects of a selective cyclooxygenase-2 inhibitor, FK3311, on warm ischemia–reperfusion injury in the lung. Male Wistar rats were divided into two groups. In the FK3311 group (n = 27), FK3311 (4 mg/kg) was administered intravenously 5 min before ischemia, while in the control group (n = 27) only vehicle was injected. Warm ischemia was induced for 1 h by clamping the left hilus. The arterial oxygen pressure (PaO2) and saturation (SaO2) were measured 30 and 120 min after reperfusion. Serum thromboxane B2 and 6-keto-prostaglandin F were also measured 30 min after reperfusion. Lung specimens were harvested 120 min after reperfusion for histologic examination and polymorphonuclear counts, and immunostained with cyclooxygenase-2. The 1-week survival rate in the two groups was compared. PaO2 and SaO2 30 and 120 min after reperfusion were significantly (p <. 05) better in the FK3311 group. Serum thromboxane B2 levels were significantly (p <. 05) lower in the FK3311 group. However, there was no significant difference in 6-keto-prostaglandin F. Histologically, tissue damage was mild and polymorphonuclear infiltration was reduced in the FK3311 group compared to the control group. The expression of cyclooxygenase-2 in the alveolar epithelium based on immunostaining was suppressed in the FK3311 group. The 1-week survival rate was significantly (p <. 05) higher in the FK3311 group. We conclude that FK3311 has protective effects on pulmonary ischemia–reperfusion injury, and results in improvement in the 1-week survival rate.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.